Short Interest in iBio, Inc. (NYSEAMERICAN:IBIO) Rises By 27.6%

iBio, Inc. (NYSEAMERICAN:IBIO) was the recipient of a significant growth in short interest in January. As of January 15th, there was short interest totalling 242,000 shares, a growth of 27.6% from the December 31st total of 189,700 shares. Approximately 2.7% of the shares of the company are sold short. Based on an average daily volume of 140,200 shares, the short-interest ratio is currently 1.7 days.

iBio Price Performance

IBIO traded up $0.04 on Friday, hitting $3.01. 241,595 shares of the company were exchanged, compared to its average volume of 266,153. The company has a debt-to-equity ratio of 0.04, a quick ratio of 0.91 and a current ratio of 0.91. iBio has a fifty-two week low of $1.05 and a fifty-two week high of $4.98.

iBio Company Profile

iBio, Inc, a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein.